BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-88. [DOI: 10.1053/j.gastro.2004.09.032] [Cited by in Crossref: 369] [Cited by in F6Publishing: 322] [Article Influence: 21.7] [Reference Citation Analysis]
Number Citing Articles
1 Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology and clinical aspects. Mol Aspects Med. 2008;29:130-143. [PMID: 18061252 DOI: 10.1016/j.mam.2007.09.008] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 4.7] [Reference Citation Analysis]
2 Goda Y, Morimoto M, Irie K, Kobayashi S, Ueno M, Moriya S, Tezuka S, Ohkawa S, Morinaga S, Numata K, Tanaka K, Maeda S. Switch to miriplatin for multinodular hepatocellular carcinoma unresponsive to transarterial chemoembolization with epirubicin: a prospective study. Japanese Journal of Clinical Oncology 2017;47:1151-6. [DOI: 10.1093/jjco/hyx131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Geller DA, Tsung A, Marsh JW, Dvorchik I, Gamblin TC, Carr BI. Outcome of 1000 liver cancer patients evaluated at the UPMC Liver Cancer Center. J Gastrointest Surg. 2006;10:63-68. [PMID: 16368492 DOI: 10.1016/j.gassur.2005.06.032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
4 Shimose S, Kawaguchi T, Iwamoto H, Niizeki T, Shirono T, Tanaka M, Koga H, Torimura T. Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma. Oncol Lett 2020;19:2667-76. [PMID: 32218817 DOI: 10.3892/ol.2020.11399] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Firouznia K, Ghanaati H, Alavian SM, Azadeh P, Nasiri Toosi M, Haj Mirzaian A, Najafi S, Shakiba M, Jalali AH. Transcatheter arterial chemoembolization therapy for patients with unresectable hepatocellular carcinoma. Hepat Mon 2014;14:e25792. [PMID: 25737732 DOI: 10.5812/hepatmon.25792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
6 Seko Y, Ikeda K, Kawamura Y, Fukushima T, Hara T, Sezaki H, Hosaka T, Akuta N, Suzuki F, Kobayashi M. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatol Res. 2013;43:942-949. [PMID: 23301851 DOI: 10.1111/hepr.12041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
7 Kirikoshi H, Saito S, Yoneda M, Fujita K, Mawatari H, Uchiyama T, Higurashi T, Goto A, Takahashi H, Abe Y. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatol Res. 2009;39:553-562. [PMID: 19527484 DOI: 10.1111/j.1872-034x.2009.00490.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
8 Adler M, De Pauw F, Vereerstraeten P, Fancello A, Lerut J, Starkel P, Van Vlierberghe H, Troisi R, Donckier V, Detry O, Delwaide J, Michielsen P, Chapelle T, Pirenne J, Nevens F. Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system. Liver Transpl 2008;14:526-33. [DOI: 10.1002/lt.21399] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
9 Chan SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World J Gastroenterol 2016;22:7289-300. [PMID: 27621575 DOI: 10.3748/wjg.v22.i32.7289] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 54] [Article Influence: 16.3] [Reference Citation Analysis]
10 Zhang XB, Wang JH, Yan ZP, Qian S, Liu R. Hepatocellular carcinoma invading the main portal vein: treatment with transcatheter arterial chemoembolization and portal vein stenting. Cardiovasc Intervent Radiol. 2009;32:52-61. [PMID: 18931871 DOI: 10.1007/s00270-008-9454-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
11 Tao R, Li X, Ran R, Xiao Z, Zhang H, Kong H, Song Q, Huang Y, Wang L, Huang J. A mixed analysis comparing nine minimally invasive surgeries for unresectable hepatocellular carcinoma patients. Oncotarget 2017;8:5460-73. [PMID: 27705924 DOI: 10.18632/oncotarget.12348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 656] [Article Influence: 62.2] [Reference Citation Analysis]
13 Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol. 2014;29:787-793. [PMID: 24224567 DOI: 10.1111/jgh.12452] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
14 Park KH, Kim JH, Choe WH, Kwon SY, Yoo BC, Hwang JH, Park SW, Kim YJ, Park HS, Yu MH, Jeon HJ. Risk Factors for Liver Function Deterioration after Transarterial Chemoembolization Refractoriness in Child-Pugh Class A Hepatocellular Carcinoma Patients. Korean J Gastroenterol 2020;75:147-56. [PMID: 32209803 DOI: 10.4166/kjg.2020.75.3.147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, Sergie Z, Wong CY, Thurston KG. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627-1639. [PMID: 16371529 DOI: 10.1097/01.rvi.0000184594.01661.81] [Cited by in Crossref: 294] [Cited by in F6Publishing: 68] [Article Influence: 19.6] [Reference Citation Analysis]
16 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 75] [Article Influence: 90.0] [Reference Citation Analysis]
17 Shim JH, Park JW, Choi JI, Kim HB, Lee WJ, Kim CM. Does postembolization fever after chemoembolization have prognostic significance for survival in patients with unresectable hepatocellular carcinoma? J Vasc Interv Radiol. 2009;20:209-216. [PMID: 19084432 DOI: 10.1016/j.jvir.2008.10.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
18 Mamori S, Asakura T, Ohkawa K, Tajiri H. Survivin expression in early hepatocellular carcinoma and post-treatment with anti-cancer drug under hypoxic culture condition. World J Gastroenterol 2007;13:5306-11. [PMID: 17879398 DOI: 10.3748/wjg.v13.i40.5306] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
19 Orsi F, Zhang L, Arnone P, Orgera G, Bonomo G, Vigna PD, Monfardini L, Zhou K, Chen W, Wang Z, Veronesi U. High-Intensity Focused Ultrasound Ablation: Effective and Safe Therapy for Solid Tumors in Difficult Locations. American Journal of Roentgenology 2010;195:W245-52. [DOI: 10.2214/ajr.09.3321] [Cited by in Crossref: 93] [Cited by in F6Publishing: 38] [Article Influence: 8.5] [Reference Citation Analysis]
20 Tsuji Y, Tsubota N, Maeda K, Nishijima E, Yamashita C, Kozawa S, Okada M, Nakamura K, Okada S. [A case of thoracic empyema with broncho-pleural fistula existing for 57 years. Histological findings of squamous cell carcinoma in the resected lung].Kyobu Geka. 1984;37:768-772. [PMID: 6503075 DOI: 10.1007/s00270-019-02169-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
21 Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, de Guevara LL, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract 2014;68:609-17. [PMID: 24283303 DOI: 10.1111/ijcp.12352] [Cited by in Crossref: 154] [Cited by in F6Publishing: 137] [Article Influence: 19.3] [Reference Citation Analysis]
22 Lee IJ, Seong J. Radiotherapeutic strategies in the management of hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:123-133. [PMID: 22212946 DOI: 10.1159/000333275] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
23 Hoffmann K, Hinz U, Hillebrand N, Radeleff BA, Ganten TM, Schirmacher P, Schmidt J, Büchler MW, Schemmer P. Risk factors of survival after liver transplantation for HCC: a multivariate single-center analysis. Clin Transplant 2011;25:E541-51. [PMID: 21518002 DOI: 10.1111/j.1399-0012.2011.01465.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
24 Song DS, Choi JY, Yoo SH, Kim HY, Song MJ, Bae SH, Yoon SK, Chun HJ, Choi BG, Lee HG. DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study. Gut Liver 2013;7:89-95. [PMID: 23424047 DOI: 10.5009/gnl.2013.7.1.89] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
25 Dorn DP, Bryant MK, Zarzour J, Smith JK, Redden DT, Saddekni S, Abdel Aal AK, Gray S, White J, Eckhoff DE, DuBay DA. Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function. HPB (Oxford) 2014;16:648-55. [PMID: 25072067 DOI: 10.1111/hpb.12194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
26 Mancuso A. Management of hepatocellular carcinoma: Enlightening the gray zones. World J Hepatol. 2013;5:302-310. [PMID: 23805354 DOI: 10.4254/wjh.v5.i6.302] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
27 Xu LF, Sun HL, Chen YT, Ni JY, Chen D, Luo JH, Zhou JX, Hu RM, Tan QY. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013;28:456-463. [PMID: 23216261 DOI: 10.1111/jgh.12088] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 5.6] [Reference Citation Analysis]
28 Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, Mamone G, Vizzini G, Luca A, Gridelli B. Efficacy of transcatheter embolization/chemoembolization (TAE/TACE) for the treatment of single hepatocellular carcinoma. World J Gastroenterol 2007;13:2952-5. [PMID: 17589945 DOI: 10.3748/wjg.v13.i21.2952] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 42] [Article Influence: 2.6] [Reference Citation Analysis]
29 Bowyer C, Lewis AL, Lloyd AW, Phillips GJ, Macfarlane WM. Hypoxia as a target for drug combination therapy of liver cancer. Anticancer Drugs 2017;28:771-80. [PMID: 28542038 DOI: 10.1097/CAD.0000000000000516] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
30 Altomonte J, Braren R, Schulz S, Marozin S, Rummeny EJ, Schmid RM, Ebert O. Synergistic antitumor effects of transarterial viroembolization for multifocal hepatocellular carcinoma in rats. Hepatology 2008;48:1864-73. [PMID: 19003878 DOI: 10.1002/hep.22546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
31 European Association for Study of Liver. European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Eur J Cancer. 2012;48:599-641. [PMID: 22424278 DOI: 10.1016/j.ejca.2011.12.021] [Cited by in Crossref: 273] [Cited by in F6Publishing: 250] [Article Influence: 30.3] [Reference Citation Analysis]
32 Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World J Gastroenterol 2019;25:4614-28. [PMID: 31528090 DOI: 10.3748/wjg.v25.i32.4614] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 17] [Article Influence: 27.0] [Reference Citation Analysis]
33 Tzeng W, Wu R, Chang S, Chou C, Lin C, Chen J, Yang S, Lin C. Ionic Versus Nonionic Contrast Media Solvents Used with an Epirubicin-based Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2008;19:342-50. [DOI: 10.1016/j.jvir.2007.10.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
34 Yamanaka K, Hatano E, Narita M, Taura K, Yasuchika K, Nitta T, Arizono S, Isoda H, Shibata T, Ikai I, Sato T, Uemoto S. Comparative study of cisplatin and epirubicin in transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparative study in TACE for HCC. Hepatology Research 2011;41:303-9. [DOI: 10.1111/j.1872-034x.2010.00770.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
35 Mizandari M, Ao G, Zhang Y, Feng X, Shen Q, Chen M, Lau W, Nicholls J, Jiao L, Habib N. Novel Percutaneous Radiofrequency Ablation of Portal Vein Tumor Thrombus: Safety and Feasibility. Cardiovasc Intervent Radiol 2013;36:245-8. [DOI: 10.1007/s00270-012-0451-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
36 Czaja AJ. Hepatocellular carcinoma and other malignancies in autoimmune hepatitis. Dig Dis Sci. 2013;58:1459-1476. [PMID: 23306849 DOI: 10.1007/s10620-012-2525-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
37 Kluger MD, Halazun KJ, Barroso RT, Fox AN, Olsen SK, Madoff DC, Siegel AB, Weintraub JL, Sussman J, Brown RS Jr, Cherqui D, Emond JC. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transpl 2014;20:536-43. [PMID: 24493271 DOI: 10.1002/lt.23846] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
38 Marcacuzco Quinto A, Nutu OA, San Román Manso R, Justo Alonso I, Calvo Pulido J, Manrique Municio A, García-Sesma Á, Loinaz Segurola C, Martínez Caballero J, Jiménez Romero LC. Complications of transarterial chemoembolization (TACE) in the treatment of liver tumors. Cir Esp (Engl Ed) 2018;96:560-7. [PMID: 30082086 DOI: 10.1016/j.ciresp.2018.06.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
39 Tsurusaki M, Murakami T. Surgical and Locoregional Therapy of HCC: TACE. Liver Cancer 2015;4:165-75. [PMID: 26675172 DOI: 10.1159/000367739] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 8.2] [Reference Citation Analysis]
40 Wrzesinski SH, Taddei TH, Strazzabosco M. Systemic therapy in hepatocellular carcinoma. Clin Liver Dis 2011;15:423-41, vii-x. [PMID: 21689622 DOI: 10.1016/j.cld.2011.03.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
41 Xu Q, Gu J, Lv Y, Yuan J, Yang N, Chen J, Wang C, Hou X, Jia X, Feng L, Yin G. Angiogenesis for tumor vascular normalization of Endostar on hepatoma 22 tumor-bearing mice is involved in the immune response. Oncol Lett 2018;15:3437-46. [PMID: 29467868 DOI: 10.3892/ol.2018.7734] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
42 Xu M, Doyle MM, Banan B, Vachharajani N, Wang X, Saad N, Fowler K, Brunt EM, Lin Y, Chapman WC. Neoadjuvant Locoregional Therapy and Recurrent Hepatocellular Carcinoma after Liver Transplantation. J Am Coll Surg. 2017;225:28-40. [PMID: 28400300 DOI: 10.1016/j.jamcollsurg.2017.03.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
43 Choi SH, Chung JW, Kim HC, Baek JH, Park CM, Jun S, Kim MU, Lee ES, Cho HR, Jae HJ. The role of perfusion CT as a follow-up modality after transcatheter arterial chemoembolization: an experimental study in a rabbit model. Invest Radiol. 2010;45:427-436. [PMID: 20440211 DOI: 10.1097/rli.0b013e3181e07516] [Cited by in Crossref: 47] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
44 Corey KE, Pratt DS. Current status of therapy for hepatocellular carcinoma. Therap Adv Gastroenterol. 2009;2:45-57. [PMID: 21180533 DOI: 10.1177/1756283X08100328] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
45 Olivo M, Valenza F, Buccellato A, Scala L, Virdone R, Sciarrino E, Di Piazza S, Marrone C, Orlando A, Fusco G. Transcatheter arterial chemoembolisation for hepatocellular carcinoma in cirrhosis: survival rate and prognostic factors. Dig Liver Dis. 2010;42:515-519. [PMID: 19914153 DOI: 10.1016/j.dld.2009.09.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
46 Yu Y, Feng M. Radiotherapy for Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:277-87. [PMID: 30309638 DOI: 10.1016/j.semradonc.2018.06.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
47 Gish RG, Gordon SC, Nelson D, Rustgi V, Rios I. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int 2009;3:480-9. [PMID: 19669251 DOI: 10.1007/s12072-009-9132-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
48 Park H, Jung JH, Jung MK, Shin EC, Ro SW, Park JH, Kim DY, Park JY, Han KH. Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma. Hepatol Int 2020;14:249-58. [PMID: 32072464 DOI: 10.1007/s12072-020-10014-4] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013;19:3872-82. [PMID: 23840128 DOI: 10.3748/wjg.v19.i24.3872] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 77] [Article Influence: 13.1] [Reference Citation Analysis]
50 Matsubara M, Shiraha H, Kataoka J, Iwamuro M, Horiguchi S, Nishina S, Takaoka N, Uemura M, Takaki A, Nakamura S. Des-γ-carboxyl prothrombin is associated with tumor angiogenesis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27:1602-1608. [PMID: 22554292 DOI: 10.1111/j.1440-1746.2012.07173.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
51 Kim YJ, Lee MH, Choi SY, Yi BH, Lee HK. Magnetic resonance imaging features predictive of an incomplete response to transarterial chemoembolization in patients with hepatocellular carcinoma: A STROBE-compliant study. Medicine (Baltimore) 2019;98:e15592. [PMID: 31083245 DOI: 10.1097/MD.0000000000015592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Peck-Radosavljevic M. Hepatocellular carcinoma: the place of new medical therapies. Therap Adv Gastroenterol 2010;3:259-67. [PMID: 21180607 DOI: 10.1177/1756283X10362278] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
53 Kumar A, Ahmad A, Vyawahare A, Khan R. Membrane Trafficking and Subcellular Drug Targeting Pathways. Front Pharmacol 2020;11:629. [PMID: 32536862 DOI: 10.3389/fphar.2020.00629] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
54 Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastro 2004;7:431-41. [DOI: 10.1007/s11938-004-0002-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
55 Hennedige T, Venkatesh SK. Imaging of hepatocellular carcinoma: diagnosis, staging and treatment monitoring. Cancer Imaging. 2013;12:530-547. [PMID: 23400006 DOI: 10.1102/1470-7330.2012.0044] [Cited by in Crossref: 86] [Cited by in F6Publishing: 59] [Article Influence: 10.8] [Reference Citation Analysis]
56 Luo LM, Xia H, Shi R, Zeng J, Liu XR, Wei M. The association between aquaporin-1 expression, microvessel density and the clinicopathological features of hepatocellular carcinoma. Oncol Lett 2017;14:7077-84. [PMID: 29344137 DOI: 10.3892/ol.2017.7106] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
57 Lee I, Huo T, Huang Y, Chao Y, Li C, Lee P, Chiang J, Su C, Lan K, Yang C, Wu J, Lin H, Lee S. Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis. Hepatol Int 2012;6:753-62. [DOI: 10.1007/s12072-011-9322-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
58 Ren J, Jia J, Zhang H, Zhang L, Ma B, Jiang H, Di L, Song G, Yu J. Dendritic cells pulsed with alpha-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma. Cancer Sci 2008;99:1420-6. [PMID: 18422751 DOI: 10.1111/j.1349-7006.2008.00820.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
59 Kohles N, Nagel D, Jüngst D, Stieber P, Holdenrieder S. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. Tumour Biol. 2012;33:2401-2409. [PMID: 22965881 DOI: 10.1007/s13277-012-0504-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
60 Zangos S, Eichler K, Balzer JO, Straub R, Hammerstingl R, Herzog C, Lehnert T, Heller M, Thalhammer A, Mack MG, Vogl TJ. Large-sized hepatocellular carcinoma (HCC): a neoadjuvant treatment protocol with repetitive transarterial chemoembolization (TACE) before percutaneous MR-guided laser-induced thermotherapy (LITT). Eur Radiol 2007;17:553-63. [PMID: 16896704 DOI: 10.1007/s00330-006-0343-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
61 Morante A, Romano M, Cuomo A, de Sio I, Cozzolino A, Mucherino C, Salerno R, Blanco CDV, Romano M. Massive gastric ulceration after transarterial chemoembolization for hepatocellular carcinoma. Gastrointestinal Endoscopy 2006;63:718-20. [DOI: 10.1016/j.gie.2005.10.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
62 Norén A, Urdzik J, Duraj F, Barbier CE, Karlson BM, Haglund U. Longterm follow-up after transarterial chemotherapy for hepatocellular carcinoma in a Scandinavian centre. HPB (Oxford) 2010;12:637-43. [PMID: 20961372 DOI: 10.1111/j.1477-2574.2010.00210.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
63 Kim J, Choi SJ, Lee SH, Lee HY, Park H. Predicting Survival Using Pretreatment CT for Patients With Hepatocellular Carcinoma Treated With Transarterial Chemoembolization: Comparison of Models Using Radiomics.AJR Am J Roentgenol. 2018;211:1026-1034. [PMID: 30240304 DOI: 10.2214/AJR.18.19507] [Cited by in Crossref: 43] [Cited by in F6Publishing: 24] [Article Influence: 14.3] [Reference Citation Analysis]
64 Chen WK, Chang YT, Chung YT, Yang HR. Outcomes of emergency treatment in ruptured hepatocellular carcinoma in the ED. Am J Emerg Med 2005;23:730-6. [PMID: 16182979 DOI: 10.1016/j.ajem.2005.02.052] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
65 Bodzin AS, Busuttil RW. Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. World J Hepatol. 2015;7:1157-1167. [PMID: 26019732 DOI: 10.4254/wjh.v7.i9.1157] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 8.2] [Reference Citation Analysis]
66 Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, Ayuso C, Castells L, Montañá X, Llovet JM, Bruix J. Chemoembolization of hepatocellular carcinoma with drug eluting beads: Efficacy and doxorubicin pharmacokinetics. Journal of Hepatology 2007;46:474-81. [DOI: 10.1016/j.jhep.2006.10.020] [Cited by in Crossref: 616] [Cited by in F6Publishing: 512] [Article Influence: 44.0] [Reference Citation Analysis]
67 Yamashita N, Izumikawa S, Takagi A, Arakawa H, Wakasawa T, Maruyama A. Preparation and characterization of gelatin sponge millispheres from air-in-water-in-oil-type emulsions. J Mater Sci Mater Med 2009;20:1299-305. [PMID: 19132505 DOI: 10.1007/s10856-008-3681-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Fitzmorris P, Shoreibah M, Anand BS, Singal AK. Management of hepatocellular carcinoma. J Cancer Res Clin Oncol 2015;141:861-76. [DOI: 10.1007/s00432-014-1806-0] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 8.4] [Reference Citation Analysis]
69 Zhu H, Zhou K, Zhang L, Jin C, Peng S, Yang W, Li K, Su H, Chen W, Bai J, Wu F, Wang Z. High intensity focused ultrasound (HIFU) therapy for local treatment of hepatocellular carcinoma: Role of partial rib resection. European Journal of Radiology 2009;72:160-6. [DOI: 10.1016/j.ejrad.2008.07.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
70 Knab LM, Salem R, Mahvi DM. Minimally invasive therapies for hepatic malignancy. Curr Probl Surg 2013;50:146-79. [PMID: 23507316 DOI: 10.1067/j.cpsurg.2013.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
71 Ayaru L, Pereira SP, Alisa A, Pathan AA, Williams R, Davidson B, Burroughs AK, Meyer T, Behboudi S. Unmasking of alpha-fetoprotein-specific CD4(+) T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol. 2007;178:1914-1922. [PMID: 17237442 DOI: 10.4049/jimmunol.178.3.1914] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 6.1] [Reference Citation Analysis]
72 Wang J, Shen JL. Spectral CT in evaluating the therapeutic effect of transarterial chemoembolization for hepatocellular carcinoma: A retrospective study. Medicine (Baltimore) 2017;96:e9236. [PMID: 29384909 DOI: 10.1097/MD.0000000000009236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
73 Shariff MI, Cox IJ, Gomaa AI, Khan SA, Gedroyc W, Taylor-robinson SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Review of Gastroenterology & Hepatology 2014;3:353-67. [DOI: 10.1586/egh.09.35] [Cited by in Crossref: 197] [Cited by in F6Publishing: 184] [Article Influence: 28.1] [Reference Citation Analysis]
74 Shen H, Agarwal D, Qi R, Chalasani N, Liangpunsakul S, Lumeng L, Yoo H, Kwo P. Predictors of outcome in patients with unresectable hepatocellular carcinoma receiving transcatheter arterial chemoembolization. Aliment Pharmacol Ther. 2007;26:393-400. [PMID: 17635374 DOI: 10.1111/j.1365-2036.2007.03395.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
75 Sacco R, Bertini M, Petruzzi P, Bertoni M, Bargellini I, Bresci G, Federici G, Gambardella L, Metrangolo S, Parisi G, Romano A, Scaramuzzino A, Tumino E, Silvestri A, Altomare E, Vignali C, Capria A. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study. World J Gastroenterol 2009;15:1843-8. [PMID: 19370781 DOI: 10.3748/wjg.15.1843] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.3] [Reference Citation Analysis]
76 Pesapane F, Nezami N, Patella F, Geschwind JF. New concepts in embolotherapy of HCC. Med Oncol. 2017;34:58. [PMID: 28299645 DOI: 10.1007/s12032-017-0917-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
77 Chen J, Lai L, Lin Q, Huang W, Cai M, Zhu K, Huang M. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study. Oncotarget 2017;8:408-17. [PMID: 27880724 DOI: 10.18632/oncotarget.13427] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
78 Yaghmai V, Besa C, Kim E, Gatlin JL, Siddiqui NA, Taouli B. Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy. American Journal of Roentgenology 2013;201:80-96. [DOI: 10.2214/ajr.13.10706] [Cited by in Crossref: 53] [Cited by in F6Publishing: 18] [Article Influence: 6.6] [Reference Citation Analysis]
79 Bonomo G, Pedicini V, Monfardini L, Della Vigna P, Poretti D, Orgera G, Orsi F. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33:552-559. [PMID: 19957182 DOI: 10.1007/s00270-009-9752-y] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 5.6] [Reference Citation Analysis]
80 Kim MJ, Jang JW, Oh BS, Kwon JH, Chung KW, Jung HS, Jekarl DW, Lee S. Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma. Cytokine. 2013;64:516-522. [PMID: 24035756 DOI: 10.1016/j.cyto.2013.07.021] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
81 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48 Suppl 1:S20-S37. [PMID: 18304676 DOI: 10.1016/j.jhep.2008.01.022] [Cited by in Crossref: 576] [Cited by in F6Publishing: 542] [Article Influence: 44.3] [Reference Citation Analysis]
82 He C, Zhang Y, Lin X. Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis. J Gastrointest Surg 2018;22:989-97. [PMID: 29435900 DOI: 10.1007/s11605-018-3703-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
83 Spangenberg HC, Thimme R, Blum HE. Advances in prevention and diagnosis of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2008;2:425-33. [PMID: 19072390 DOI: 10.1586/17474124.2.3.425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
84 Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A, Farinati F. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103:914-921. [PMID: 18177453 DOI: 10.1111/j.1572-0241.2007.01712.x] [Cited by in Crossref: 258] [Cited by in F6Publishing: 257] [Article Influence: 19.8] [Reference Citation Analysis]
85 Real M, Bianchi L, Vilana R, Burrel M, Rimola J. Tratamiento percutáneo e intraarterial del carcinoma hepatocelular. Radiología 2010;52:399-413. [DOI: 10.1016/j.rx.2010.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 Wu J, Bai W, Han G, Fan D. ART score for retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma: Is it really applicable? Journal of Hepatology 2014;61:176-7. [DOI: 10.1016/j.jhep.2014.02.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Higgins LJ, Hwang GL, Rosenberg J, Katzenberg RH, Kothary N, Sze DY, Hofmann LV. In Vitro Design and Characterization of the Nonviral Gene Delivery Vector Iopamidol, Protamine, Ethiodized Oil Reagent. Journal of Vascular and Interventional Radiology 2011;22:1457-1463.e2. [DOI: 10.1016/j.jvir.2011.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
88 Kim H, Chung JW, Choi SH, Im S, Yamasaki Y, Jun S, Jae HJ, Park JH. Augmentation of Chemotherapeutic Infusion Effect by TSU-68, an Oral Targeted Antiangiogenic Agent, in a Rabbit VX2 Liver Tumor Model. Cardiovasc Intervent Radiol 2012;35:168-75. [DOI: 10.1007/s00270-010-0081-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
89 Xing M, Kokabi N, Camacho JC, Kooby DA, El-Rayes BF, Kim HS. 90Y radioembolization versus chemoembolization in the treatment of hepatocellular carcinoma: an analysis of comparative effectiveness. J Comp Eff Res 2013;2:435-44. [PMID: 24236684 DOI: 10.2217/cer.13.37] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
90 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Reference Citation Analysis]
91 Chevallier P, Baudin G, Anty R, Guibal A, Chassang M, Avril L, Tran A. Treatment of hepatocellular carcinomas by thermal ablation and hepatic transarterial chemoembolization. Diagnostic and Interventional Imaging 2015;96:637-46. [DOI: 10.1016/j.diii.2015.04.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
92 Wong N, Haydon A, Kemp W, Wijeratne P, Roberts S. Improved survival trend of patients with hepatocellular carcinoma at an Australian tertiary hospital between 1995-2009. Intern Med J 2013;43:197-203. [PMID: 22372378 DOI: 10.1111/j.1445-5994.2012.02755.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
93 Vinh NQ, Naka S, Cabral H, Murayama H, Kaida S, Kataoka K, Morikawa S, Tani T. MRI-detectable polymeric micelles incorporating platinum anticancer drugs enhance survival in an advanced hepatocellular carcinoma model. Int J Nanomedicine 2015;10:4137-47. [PMID: 26203241 DOI: 10.2147/IJN.S81339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
94 Liapi E, Geschwind JF. Chemoembolization for primary and metastatic liver cancer. Cancer J. 2010;156-162. [PMID: 20404613 DOI: 10.1097/ppo.0b013e3181d7e905] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
95 Jung ES, Kim JH, Yoon EL, Lee HJ, Lee SJ, Suh SJ, Lee BJ, Seo YS, Yim HJ, Seo TS. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol. 2013;58:1181-1187. [PMID: 23395691 DOI: 10.1016/j.jhep.2013.01.039] [Cited by in Crossref: 82] [Cited by in F6Publishing: 77] [Article Influence: 10.3] [Reference Citation Analysis]
96 Richani M, Kolly P, Knoepfli M, Herrmann E, Zweifel M, Tengg-kobligk HV, Candinas D, Dufour J. Treatment allocation in hepatocellular carcinoma: Assessment of the BCLC algorithm. Annals of Hepatology 2016;15:82-90. [DOI: 10.5604/16652681.1184233] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
97 Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012;17:359-366. [PMID: 22334456 DOI: 10.1634/theoncologist.2011-0313] [Cited by in Crossref: 105] [Cited by in F6Publishing: 108] [Article Influence: 11.7] [Reference Citation Analysis]
98 Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. [PMID: 27158749 DOI: 10.1038/nrdp.2016.18] [Cited by in Crossref: 941] [Cited by in F6Publishing: 865] [Article Influence: 188.2] [Reference Citation Analysis]
99 Antoch G, Roelle G, Ladd SC, Kuehl H, Heusner TA, Sotiropoulos GC, Hilgard P, Forsting M, Verhagen R. Selective and sequential transarterial chemoembolization: survival in patients with hepatocellular carcinoma. Eur J Radiol. 2012;81:2290-2297. [PMID: 21978775 DOI: 10.1016/j.ejrad.2011.09.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
100 Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the treatment of hepatocellular carcinoma. Biologics 2008;2:453-62. [PMID: 19707376 DOI: 10.2147/btt.s3254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
101 López-benítez R, Radeleff B, Barragán-campos H, Noeldge G, Grenacher L, Richter G, Sauer P, Büchler M, Kauffmann G, Hallscheidt P. Acute Pancreatitis after Embolization of Liver Tumors: Frequency and Associated Risk Factors. Pancreatology 2007;7:53-62. [DOI: 10.1159/000101878] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
102 Bai M, Reynolds NR, Mccorkle R. The promise of clinical interventions for hepatocellular carcinoma from the west to mainland China. Pall Supp Care 2013;11:503-22. [DOI: 10.1017/s1478951512001137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Rossi L, Zoratto F, Papa A, Iodice F, Minozzi M, Frati L, Tomao S. Current approach in the treatment of hepatocellular carcinoma. World J Gastrointest Oncol. 2010;2:348-359. [PMID: 21160806 DOI: 10.4251/wjgo.v2.i9.348] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
104 Muhammad A, Dhamija M, Vidyarthi G, Amodeo D, Boyd W, Miladinovic B, Kumar A. Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma. World J Hepatol. 2013;5:364-371. [PMID: 23898369 DOI: 10.4254/wjh.v5.i7.364] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
105 Arizumi T, Ueshima K, Minami T, Kono M, Chishina H, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer. 2015;4:253-262. [PMID: 26734579 DOI: 10.1159/000367743] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 12.2] [Reference Citation Analysis]
106 Koga C, Kobayashi S, Nagano H, Tomimaru Y, Hama N, Wada H, Kawamoto K, Eguchi H, Konno M, Ishii H, Umeshita K, Doki Y, Mori M. Reprogramming using microRNA-302 improves drug sensitivity in hepatocellular carcinoma cells. Ann Surg Oncol 2014;21 Suppl 4:S591-600. [PMID: 24740829 DOI: 10.1245/s10434-014-3705-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
107 Riaz A, Memon K, Miller FH, Nikolaidis P, Kulik LM, Lewandowski RJ, Ryu RK, Sato KT, Gates VL, Mulcahy MF. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol. 2011;54:695-704. [PMID: 21147504 DOI: 10.1016/j.jhep.2010.10.004] [Cited by in Crossref: 124] [Cited by in F6Publishing: 104] [Article Influence: 11.3] [Reference Citation Analysis]
108 Ma Y, Duan L, Li L, Lu W, Li B, Chen X. 131Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment. J Gastrointest Oncol 2021;12:762-9. [PMID: 34012664 DOI: 10.21037/jgo-21-105] [Reference Citation Analysis]
109 Padma S, Martinie JB, Iannitti DA. Liver tumor ablation: Percutaneous and open approaches. J Surg Oncol. 2009;100:619-634. [PMID: 20017157 DOI: 10.1002/jso.21364] [Cited by in Crossref: 68] [Cited by in F6Publishing: 53] [Article Influence: 6.2] [Reference Citation Analysis]
110 Bruix J, Sherman M;  Practice Guidelines Committee;  American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. [PMID: 16250051 DOI: 10.1002/hep.20933] [Cited by in Crossref: 4104] [Cited by in F6Publishing: 3746] [Article Influence: 256.5] [Reference Citation Analysis]
111 Khalaf MH, Shah RP, Green V, Vezeridis AM, Liang T, Kothary N. Comparison of Opioid Medication Use after Conventional Chemoembolization versus Drug-Eluting Embolic Chemoembolization. J Vasc Interv Radiol 2020;31:1292-9. [PMID: 32654960 DOI: 10.1016/j.jvir.2020.04.018] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
112 Zhao B, Lu J, Yin J, Liu H, Guo X, Yang Y, Ge N, Zhu Y, Zhang H, Xing J. A functional polymorphism in PER3 gene is associated with prognosis in hepatocellular carcinoma. Liver Int. 2012;32:1451-1459. [PMID: 22809120 DOI: 10.1111/j.1478-3231.2012.02849.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
113 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol. 2007;13:3164-3170. [PMID: 17589893 DOI: 10.3748/wjg.v13.i13.3164] [Reference Citation Analysis]
114 Forner A, Hessheimer AJ, Isabel Real M, Bruix J. Treatment of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2006;60:89-98. [DOI: 10.1016/j.critrevonc.2006.06.001] [Cited by in Crossref: 104] [Cited by in F6Publishing: 91] [Article Influence: 6.9] [Reference Citation Analysis]
115 Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20:5442-5460. [PMID: 24833875 DOI: 10.3748/wjg.v20.i18.5442] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 66] [Article Influence: 14.5] [Reference Citation Analysis]
116 Au JS, Frenette CT. Management of Hepatocellular Carcinoma: Current Status and Future Directions. Gut Liver. 2015;9:437-448. [PMID: 26087860 DOI: 10.5009/gnl15022] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
117 Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. Aliment Pharmacol Ther. 2006;23:1535-1547. [PMID: 16696801 DOI: 10.1111/j.1365-2036.2006.02932.x] [Cited by in Crossref: 250] [Cited by in F6Publishing: 210] [Article Influence: 16.7] [Reference Citation Analysis]
118 Boige V, Raoul JL, Pignon JP, Bouché O, Blanc JF, Dahan L, Jouve JL, Dupouy N, Ducreux M; Fédération Francophone de Cancérologie Digestive. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer 2007;97:862-7. [PMID: 17876335 DOI: 10.1038/sj.bjc.6603956] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 4.1] [Reference Citation Analysis]
119 Min JH, Lee MW, Rhim H, Choi D, Kim Y, Kim YJ, Cha DI, Lim HK. Recurrent Hepatocellular Carcinoma After Transcatheter Arterial Chemoembolization: Planning Sonography for Radio Frequency Ablation. Journal of Ultrasound in Medicine 2011;30:617-24. [DOI: 10.7863/jum.2011.30.5.617] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
120 Park SY, Han J, Kim JB, Yang M, Kim YJ, Lim H, An SY, Kim J. Interleukin-8 is related to poor chemotherapeutic response and tumourigenicity in hepatocellular carcinoma. European Journal of Cancer 2014;50:341-50. [DOI: 10.1016/j.ejca.2013.09.021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
121 He CB, Lin XJ. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101. PLoS One 2017;12:e0174769. [PMID: 28355305 DOI: 10.1371/journal.pone.0174769] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 5.5] [Reference Citation Analysis]
122 Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005;11:6104-9. [PMID: 16273634 DOI: 10.3748/wjg.v11.i39.6104] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
123 Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol. 2012;18:1933-1939. [PMID: 22563174 DOI: 10.3748/wjg.v18.i16.1933] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
124 European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943. [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001] [Cited by in Crossref: 3642] [Cited by in F6Publishing: 3268] [Article Influence: 404.7] [Reference Citation Analysis]
125 Zhang X, Zhuang Z, Ye H, Beilner J, Kowarschik M, Chen J, Chi J, Xu J. Objective Assessment of Transcatheter Arterial Chemoembolization Angiographic Endpoints: Preliminary Study of Quantitative Digital Subtraction Angiography. Journal of Vascular and Interventional Radiology 2013;24:667-71. [DOI: 10.1016/j.jvir.2013.01.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
126 Lennerz JK, Crippin JS, Brunt EM. Diagnostic Considerations of Nodules in the Cirrhotic Liver: A Case-Based Perspective. Pathology Case Reviews 2009;14:3-12. [DOI: 10.1097/pcr.0b013e31819c4238] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
127 Guo TK, Hao XY, Ma B, Yang KH, Li YP, Li HL, Gu YH, Cai H, Liu YL, Li Y, Zhan WP. Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol 2009;135:1685-92. [PMID: 19536563 DOI: 10.1007/s00432-009-0615-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
128 Varghese J, Kedarisetty CK, Venkataraman J, Srinivasan V, Deepashree T, Uthappa MC, Ilankumaran K, Govil S, Srinivas Reddy M, Rela M. Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience. Annals of Hepatology 2017;16:247-54. [DOI: 10.5604/16652681.1231585] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
129 Miura JT, Rilling WS, White SB, Hieb RA, Tutton SM, Patel PJ, Gamblin TC, Hohenwalter EJ. Safety and efficacy of transarterial chemoembolization in patients with transjugular intrahepatic portosystemic shunts. HPB (Oxford). 2015;17:707-712. [PMID: 26172137 DOI: 10.1111/hpb.12433] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
130 Li WF, Al-Taher M, Yu CY, Liu YW, Liu YY, Marescaux J, Cheng YF, Diana M, Wang CC. Super-Selective Intra-Arterial Indocyanine Green Administration for Near-Infrared Fluorescence-Based Positive Staining of Hepatic Segmentation: A Feasibility Study. Surg Innov 2021;:1553350621996972. [PMID: 33787401 DOI: 10.1177/1553350621996972] [Reference Citation Analysis]
131 Cai Y, Chang Q, Xiao E, Shang QL, Chen Z. Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e10890. [PMID: 29851811 DOI: 10.1097/MD.0000000000010890] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Olsen SK, Brown RS, Siegel AB. Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. Therap Adv Gastroenterol. 2010;3:55-66. [PMID: 21180590 DOI: 10.1177/1756283x09346669] [Cited by in Crossref: 49] [Cited by in F6Publishing: 34] [Article Influence: 4.9] [Reference Citation Analysis]
133 Jang JW, Choi JY, Bae SH, Yoon SK, Woo HY, Chang UI, Kim CW, Nam SW, Cho SH, Yang JM. The impact of hepatitis B viral load on recurrence after complete necrosis in patients with hepatocellular carcinoma who receive transarterial chemolipiodolization: implications for viral suppression to reduce the risk of cancer recurrence. Cancer. 2007;110:1760-1767. [PMID: 17724708 DOI: 10.1002/cncr.22984] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
134 Wang D, Gaba RC, Jin B, Lewandowski RJ, Riaz A, Memon K, Ryu RK, Sato KT, Kulik LM, Mulcahy MF, Larson AC, Salem R, Omary RA. Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma. Radiology 2014;272:587-97. [PMID: 24678859 DOI: 10.1148/radiol.14131311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
135 Kedarisetty CK, Bal S, Parida S, Jain M, Bhadoria AS, Varghese J, Venkataraman J. Role of N-acetyl Cysteine in Post-transarterial Chemoembolization Transaminitis in Hepatocellular Carcinoma: A Single-center Experience. J Clin Exp Hepatol 2021;11:299-304. [PMID: 33994712 DOI: 10.1016/j.jceh.2020.10.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Cao ZY, Chen XZ, Liao LM, Peng J, Hu HX, Liu ZZ, Du J. Fuzheng Yiliu Granule inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro. Chin J Integr Med. 2011;17:691-697. [PMID: 21910071 DOI: 10.1007/s11655-011-0847-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
137 Majno P, Giostra E, Mentha G. Management of hepatocellular carcinoma on the waiting list before liver transplantation: Time for controlled trials? Liver Transpl 2007;13:S27-35. [DOI: 10.1002/lt.21328] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
138 Wei X, Zhao L, Ren R, Ji F, Xue S, Zhang J, Liu Z, Ma Z, Wang XW, Wong L, Liu N, Shi J, Guo X, Roessler S, Zheng X, Ji J. MiR-125b Loss Activated HIF1α/pAKT Loop, Leading to Transarterial Chemoembolization Resistance in Hepatocellular Carcinoma. Hepatology 2021;73:1381-98. [PMID: 32609900 DOI: 10.1002/hep.31448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
139 Guiu B, Colin C, Cercueil J, Loffroy R, Guiu S, Ferrant E, Jouve J, Bonnetain F, Boulin M, Ghiringhelli F, Minello A, Hillon P, Bedenne L, Krause D, Chauffert B. Pilot Study of Transarterial Chemoembolization With Pirarubicin and Amiodarone for Unresectable Hepatocellular Carcinoma. American Journal of Clinical Oncology 2009;32:238-44. [DOI: 10.1097/coc.0b013e3181845529] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
140 Forner A, Real MI, Varela M, Bruix J. Transarterial chemoembolization for patients with hepatocellular carcinoma. Hepatology Research 2007;37:S230-7. [DOI: 10.1111/j.1872-034x.2007.00190.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
141 El Fouly A, Ertle J, El Dorry A, Shaker MK, Dechêne A, Abdella H, Mueller S, Barakat E, Lauenstein T, Bockisch A, Gerken G, Schlaak JF. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization? Liver Int 2015;35:627-35. [DOI: 10.1111/liv.12637] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 8.3] [Reference Citation Analysis]
142 Yamanaka K, Hatano E, Kitamura K, Iida T, Ishii T, Machimito T, Taura K, Yasuchika K, Isoda H, Shibata T. Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma. J Gastroenterol. 2012;47:343-346. [PMID: 22183859 DOI: 10.1007/s00535-011-0511-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
143 Chen X, Liu L, Pan X. Portal vein tumor thrombus in advanced hepatocellular carcinoma: A case report. Oncol Lett 2015;9:2495-8. [PMID: 26137096 DOI: 10.3892/ol.2015.3115] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
144 Vogl TJ, Naguib NN, Nour-eldin NA, Rao P, Emami AH, Zangos S, Nabil M, Abdelkader A. Review on transarterial chemoembolization in hepatocellular carcinoma: Palliative, combined, neoadjuvant, bridging, and symptomatic indications. European Journal of Radiology 2009;72:505-16. [DOI: 10.1016/j.ejrad.2008.08.007] [Cited by in Crossref: 85] [Cited by in F6Publishing: 72] [Article Influence: 7.1] [Reference Citation Analysis]
145 Bu Y, Jia QA, Ren ZG, Zhang JB, Jiang XM, Liang L, Xue TC, Zhang QB, Wang YH, Zhang L, Xie XY, Tang ZY. Maintenance of stemness in oxaliplatin-resistant hepatocellular carcinoma is associated with increased autocrine of IGF1. PLoS One 2014;9:e89686. [PMID: 24632571 DOI: 10.1371/journal.pone.0089686] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
146 Ha Y, Han S, Shim JH, Ko GY, Yoon HK, Sung KB, Lee D, Kim KM, Lim YS, Chung YH, Lee YS, Lee HC. Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. J Vasc Interv Radiol 2015;26:1093-1101.e1. [PMID: 26077020 DOI: 10.1016/j.jvir.2015.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
147 Song MJ, Bae SH, Lee JS, Lee SW, Song DS, You CR, Choi JY, Yoon SK. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. Korean J Intern Med. 2016;31:242-252. [PMID: 26874512 DOI: 10.3904/kjim.2015.112] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
148 Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol. 2005;11:7391-7400. [PMID: 16437707 DOI: 10.3748/wjg.v11.i47.7391] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 91] [Article Influence: 2.4] [Reference Citation Analysis]
149 Chen CS, Li FK, Guo CY, Xiao JC, Hu HT, Cheng HT, Zheng L, Zong DW, Ma JL, Jiang L, Li HL. Tumor vascularity and lipiodol deposition as early radiological markers for predicting risk of disease progression in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Oncotarget 2016;7:7241-52. [PMID: 26769845 DOI: 10.18632/oncotarget.6892] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
150 Liu X, Cheng Q, Geng W, Ling C, Liu Y, Ng KT, Yam JW, Guan X, Lo C, Man K. Enhancement of cisplatin-based TACE by a hemoglobin-based oxygen carrier in an orthotopic rat HCC model. Artificial Cells, Nanomedicine, and Biotechnology 2013;42:229-36. [DOI: 10.3109/21691401.2013.808647] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
151 Huang JH, Gao F, Gu YK, Li WQ, Lu LW. Combined treatment of hepatocellular carcinoma with partial splenic embolization and transcatheter hepatic arterial chemoembolization. World J Gastroenterol 2007;13:6593-7. [PMID: 18161933 DOI: 10.3748/wjg.v13.i48.6593] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
152 Pompili M, Riccardi L, Covino M, Barbaro B, Di Stasi C, Orefice R, Gasbarrini G, Rapaccini GL. Contrast-enhanced gray-scale harmonic ultrasound in the efficacy assessment of ablation treatments for hepatocellular carcinoma. Liver Int. 2005;25:954-961. [PMID: 16162152 DOI: 10.1111/j.1478-3231.2005.01135.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
153 Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol. 2005;70:1568-1578. [PMID: 16226226 DOI: 10.1016/j.bcp.2005.09.007] [Cited by in Crossref: 111] [Cited by in F6Publishing: 98] [Article Influence: 6.9] [Reference Citation Analysis]
154 Marin D, Cappabianca S, Serra N, Sica A, Lassandro F, D'Angelo R, La Porta M, Fiore F, Somma F. CT Appearance of Hepatocellular Carcinoma after Locoregional Treatments: A Comprehensive Review. Gastroenterol Res Pract 2015;2015:670965. [PMID: 26798332 DOI: 10.1155/2015/670965] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
155 Zhu CB, Wang C, Chen LL, Ma GL, Zhang SC, Su L, Tian JJ, Gai ZT. Serum YKL-40 independently predicts outcome after transcatheter arterial chemoembolization of hepatocellular carcinoma. PLoS One 2012;7:e44648. [PMID: 22970277 DOI: 10.1371/journal.pone.0044648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
156 Chen S, Zhang K, Liu W, Yu W. Hepatic arterial infusion of oxaliplatin plus raltitrexed in patients with intermediate and advanced stage hepatocellular carcinoma: A phase II, single-arm, prospective study. Eur J Cancer 2020;134:90-8. [PMID: 32497895 DOI: 10.1016/j.ejca.2020.03.032] [Reference Citation Analysis]
157 Yu SC, Hui JW, Hui EP, Chan SL, Lee KF, Mo F, Wong J, Ma B, Lai P, Mok T. Unresectable hepatocellular carcinoma: randomized controlled trial of transarterial ethanol ablation versus transcatheter arterial chemoembolization. Radiology. 2014;270:607-620. [PMID: 24126369 DOI: 10.1148/radiol.13130498] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
158 Yang Y, Wang C, Lu Y, Bai W, An L, Qu J, Gao X, Chen Y, Zhou L, Wu Y, Feng Y, Zhang M, Chang X, Lv J. Outcomes of ultrasound-guided percutaneous argon-helium cryoablation of hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2012;19:674-84. [PMID: 22187145 DOI: 10.1007/s00534-011-0490-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
159 Wan YM, Li YH, Xu ZY, Wu HM, Xu Y, Yang M, Wu XN. The Effect of Transarterial Chemoembolization in Combination With Kang'ai Injection on Patients With Intermediate Stage Hepatocellular Carcinoma: A Prospective Study. Integr Cancer Ther 2018;17:477-85. [PMID: 29108428 DOI: 10.1177/1534735417734913] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
160 Zhang L, Hu P, Chen X, Bie P. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One 2014;9:e100305. [PMID: 24945380 DOI: 10.1371/journal.pone.0100305] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 9.3] [Reference Citation Analysis]
161 Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol. 2009;10:425-434. [PMID: 19721826 DOI: 10.3348/kjr.2009.10.5.425] [Cited by in Crossref: 96] [Cited by in F6Publishing: 83] [Article Influence: 8.0] [Reference Citation Analysis]
162 Choi JW, Park JY, Ahn SH, Yoon KT, Ko HK, Lee DY, Lee JT, Kim KS, Choi JS, Han KH. Efficacy and safety of transarterial chemoembolization in recurrent hepatocellular carcinoma after curative surgical resection. Am J Clin Oncol. 2009;32:564-569. [PMID: 19564783 DOI: 10.1097/COC.0b013e3181967da0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
163 Cheng Z, Wang K, Wei J, Lu X, Liu B. Proteomic analysis of anti-tumor effects by tetrandrine treatment in HepG2 cells. Phytomedicine 2010;17:1000-5. [DOI: 10.1016/j.phymed.2010.03.018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
164 Kawaoka T, Aikata H, Takaki S, Hashimoto Y, Katamura Y, Hiramatsu A, Waki K, Takahashi S, Kamada K, Kitamoto M. Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems. Hepatol Res. 2010;40:1082-1091. [PMID: 20880059 DOI: 10.1111/j.1872-034x.2010.00714.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
165 Arii S, Sata M, Sakamoto M, Shimada M, Kumada T, Shiina S, Yamashita T, Kokudo N, Tanaka M, Takayama T, Kudo M. Management of hepatocellular carcinoma: Report of Consensus Meeting in the 45th Annual Meeting of the Japan Society of Hepatology (2009). Hepatol Res. 2010;40:667-685. [PMID: 20633193 DOI: 10.1111/j.1872-034x.2010.00673.x] [Cited by in Crossref: 129] [Cited by in F6Publishing: 45] [Article Influence: 12.9] [Reference Citation Analysis]
166 Seinstra BA, van Delden OM, van Erpecum KJ, van Hillegersberg R, Mali WP, van den Bosch MA. Minimally invasive image-guided therapy for inoperable hepatocellular carcinoma: What is the evidence today? Insights Imaging. 2010;1:167-181. [PMID: 23100194 DOI: 10.1007/s13244-010-0027-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
167 Zhao H, Zhao Y, Guo Y, Huang Y, Lin S, Xue C, Xu F, Zhang Y, Zhao L, Hu Z, Zhang L. Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment. Onco Targets Ther 2013;6:811-8. [PMID: 23861589 DOI: 10.2147/OTT.S46498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
168 Zhang YF, Zhou J, Wei W, Zou RH, Chen MS, Lau WY, Shi M, Guo RP. Intermediate-stage hepatocellular carcinoma treated with hepatic resection: the NSP score as an aid to decision-making. Br J Cancer. 2016;115:1039-1047. [PMID: 27701389 DOI: 10.1038/bjc.2016.301] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
169 Huynh CT, Nguyen QV, Lym JS, Kim BS, Huynh DP, Jae HJ, Kim YI, Lee DS. Intraarterial gelation of injectable cationic pH/temperature-sensitive radiopaque embolic hydrogels in a rabbit hepatic tumor model and their potential application for liver cancer treatment. RSC Adv 2016;6:47687-97. [DOI: 10.1039/c6ra03263j] [Cited by in Crossref: 13] [Article Influence: 2.6] [Reference Citation Analysis]
170 Lee IJ, Seong J. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver 2012;6:139-48. [PMID: 22570744 DOI: 10.5009/gnl.2012.6.2.139] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
171 Tian Y, Lyu H, He Y, Kanduri HK. Evaluating the Ability of the New Subclassification to Prognosticate Outcomes Following Hepatectomy for Patients with HBV-Related HCC. J Gastrointest Cancer 2019;50:400-7. [PMID: 29512001 DOI: 10.1007/s12029-018-0085-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
172 Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int. 2013;33:327-337. [PMID: 23331661 DOI: 10.1111/liv.12083] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
173 Shiozawa K, Watanabe M, Ikehara T, Shimizu R, Shinohara M, Igarashi Y, Sumino Y. Evaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography. J Med Ultrason (2001) 2017;44:101-7. [PMID: 27837395 DOI: 10.1007/s10396-016-0757-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
174 Zeng W, Gouw AS, van den Heuvel MC, Zwiers PJ, Zondervan PE, Poppema S, Zhang N, Platteel I, de Jong KP, Molema G. The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization. Hepatology. 2008;48:1517-1527. [PMID: 18924243 DOI: 10.1002/hep.22490] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
175 Koom WS, Seong J, Han KH, Lee do Y, Lee JT. Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas? Int J Radiat Oncol Biol Phys. 2010;77:1433-1440. [PMID: 19896779 DOI: 10.1016/j.ijrobp.2009.07.1676] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
176 Liang B, Xiong F, Wu H, Wang Y, Dong X, Cheng S, Feng G, Zhou G, Xiong B, Liang H, Xia X, Zheng C. Effect of transcatheter intraarterial therapies on the distribution of Doxorubicin in liver cancer in a rabbit model. PLoS One 2013;8:e76388. [PMID: 24116106 DOI: 10.1371/journal.pone.0076388] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
177 Lewis AL, Gonzalez MV, Leppard SW, Brown JE, Stratford PW, Phillips GJ, Lloyd AW. Doxorubicin eluting beads - 1: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med. 2007;18:1691-1699. [PMID: 17483878 DOI: 10.1007/s10856-007-3068-8] [Cited by in Crossref: 121] [Cited by in F6Publishing: 104] [Article Influence: 8.6] [Reference Citation Analysis]
178 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 98] [Article Influence: 19.7] [Reference Citation Analysis]
179 Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene. 2006;25:3848-3856. [PMID: 16799626 DOI: 10.1038/sj.onc.1209548] [Cited by in Crossref: 109] [Cited by in F6Publishing: 94] [Article Influence: 7.3] [Reference Citation Analysis]
180 Lee IJ, Seong J. Radiosensitizers in Hepatocellular Carcinoma. Seminars in Radiation Oncology 2011;21:303-11. [DOI: 10.1016/j.semradonc.2011.05.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
181 Oikonomopoulos G, Aravind P, Sarker D. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma? Future Oncology 2016;12:465-76. [DOI: 10.2217/fon.15.341] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
182 Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD, Li LQ. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis. Ann Surg Oncol. 2014;21:3069-3076. [PMID: 24728740 DOI: 10.1245/s10434-014-3704-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
183 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
184 Melchiorre F, Patella F, Pescatori L, Pesapane F, Fumarola E, Biondetti P, Brambillasca P, Monaco C, Ierardi AM, Franceschelli G, Carrafiello G. DEB-TACE: a standard review. Future Oncol. 2018;14:2969-2984. [PMID: 29987957 DOI: 10.2217/fon-2018-0136] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
185 Perumalswami PV, Schiano TD. The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci 2011;56:1266-81. [PMID: 21416246 DOI: 10.1007/s10620-011-1619-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
186 Hata M, Tokuuye K, Sugahara S, Tohno E, Nakayama H, Fukumitsu N, Mizumoto M, Abei M, Shoda J, Minami M, Akine Y. Proton Beam Therapy for Aged Patients With Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics 2007;69:805-12. [DOI: 10.1016/j.ijrobp.2007.04.016] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
187 Riaz A, Lewandowski RJ, Kulik L, Ryu RK, Mulcahy MF, Baker T, Gates V, Nayar R, Wang E, Miller FH. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol. 2010;33:1143-1152. [PMID: 19967371 DOI: 10.1007/s00270-009-9766-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
188 Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology. 2009;250:466-473. [PMID: 19188315 DOI: 10.1148/radiol.2502072222] [Cited by in Crossref: 144] [Cited by in F6Publishing: 132] [Article Influence: 12.0] [Reference Citation Analysis]
189 Choi SJ, Kim J, Kim HS, Park H. Parametric response mapping of dynamic CT: enhanced prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization. Abdom Radiol (NY) 2017;42:1871-9. [PMID: 28204855 DOI: 10.1007/s00261-017-1082-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
190 Mamori S, Nagatsuma K, Matsuura T, Ohkawa K, Hano H, Fukunaga M, Matsushima M, Masui Y, Fushiya N, Onoda H, Searashi Y, Takagi I, Tagiri H. Useful detection of CD147 (EMMPRIN) for pathological diagnosis of early hepatocellular carcinoma in needle biopsy samples. World J Gastroenterol 2007;13:2913-7. [PMID: 17589939 DOI: 10.3748/wjg.v13.i21.2913] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
191 Carugo D, Capretto L, Roy B, Carboni M, Caine M, Lewis AL, Hill M, Chakraborty S, Zhang X. Spatiotemporal dynamics of doxorubicin elution from embolic beads within a microfluidic network. Journal of Controlled Release 2015;214:62-75. [DOI: 10.1016/j.jconrel.2015.07.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
192 Helmberger T, Hoffmann RT, Jakobs T, Leibecke T, Lubienski A, Reiser M. [Liver tumor ablation]. Radiologe. 2005;45:55-62. [PMID: 15609015 DOI: 10.1007/s00117-004-1149-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
193 Matsui Y, Figi A, Horikawa M, Jahangiri Noudeh Y, Tomozawa Y, Hashimoto K, Kaufman J, Farsad K. Arteriopathy after transarterial chemo-lipiodolization for hepatocellular carcinoma. Diagnostic and Interventional Imaging 2017;98:827-35. [DOI: 10.1016/j.diii.2017.10.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
194 Wu J, Song L, Zhao DY, Guo B, Liu J. Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2014;20:10960-8. [PMID: 25152600 DOI: 10.3748/wjg.v20.i31.10960] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
195 Hong K, Georgiades CS, Geschwind JF. Technology insight: Image-guided therapies for hepatocellular carcinoma--intra-arterial and ablative techniques. Nat Clin Pract Oncol. 2006;3:315-324. [PMID: 16757969 DOI: 10.1038/ncponc0512] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
196 Hong K, Geschwind JH. Locoregional Intra-arterial Therapies for Unresectable Intrahepatic Cholangiocarcinoma. Seminars in Oncology 2010;37:110-7. [DOI: 10.1053/j.seminoncol.2010.03.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
197 Gaba RC, Jin B, Wang D, Lewandowski RJ, Ragin AB, Larson AC, Salem R, Omary RA. Locoregional Chemoembolic Delivery: Prediction With Transcatheter Intraarterial Perfusion MRI. American Journal of Roentgenology 2012;198:1196-202. [DOI: 10.2214/ajr.11.7412] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
198 Wu Y, Guo L, Liu J, Liu R, Liu M, Chen J. [The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells]. Zhongguo Fei Ai Za Zhi 2014;17:1-7. [PMID: 24398307 DOI: 10.3779/j.issn.1009-3419.2014.01.01] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
199 Mannelli L, Kim S, Hajdu CH, Babb JS, Taouli B. Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: Prediction and assessment of response to transarterial chemoembolization. Preliminary experience. Eur J Radiol. 2013;82:577-582. [PMID: 23246330 DOI: 10.1016/j.ejrad.2012.11.026] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
200 Ikeda M, Okusaka T, Ueno H, Morizane C, Iwasa S, Hagihara A, Kojima Y. Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. Oncology 2007;72:188-93. [PMID: 18097170 DOI: 10.1159/000112805] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
201 Tipaldi MA, Ronconi E, Lucertini E, Krokidis M, Zerunian M, Polidori T, Begini P, Marignani M, Mazzuca F, Caruso D, Rossi M, Laghi A. Hepatocellular Carcinoma Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE): Outcome Analysis Using a Model Based On Pre-Treatment CT Texture Features. Diagnostics (Basel) 2021;11:956. [PMID: 34073545 DOI: 10.3390/diagnostics11060956] [Reference Citation Analysis]
202 Theodoropoulos J, Brooks A. Inconsistency in the Management of Patients with Hepatocellular Carcinoma: The Need for a Strict Protocol. The American Surgeon 2011;77:207-14. [DOI: 10.1177/000313481107700223] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
203 Lopez PM, Villanueva A, Roayaie S, Llovet JM. Neoadjuvant therapies for hepatocellular carcinoma before liver transplantation: a critical appraisal. Liver Transpl. 2006;12:1747-1754. [PMID: 17133591 DOI: 10.1002/lt.21018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
204 Omyła-Staszewska J, Deptała A. Effective therapeutic management of hepatocellular carcinoma - on the basis of a clinical case. Contemp Oncol (Pozn) 2012;16:60-3. [PMID: 23788857 DOI: 10.5114/wo.2012.27339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
205 Ni J, Liu S, Xu L, Sun H, Chen Y. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013;139:653-9. [DOI: 10.1007/s00432-012-1369-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
206 Fatourou EM, Tsochatzis EA. ART and science in using transarterial chemoembolization for retreating patients with hepatocellular carcinoma. Hepatobiliary Surg Nutr 2014;3:415-8. [PMID: 25568865 DOI: 10.3978/j.issn.2304-3881.2014.07.01] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
207 Makary MS, Kapke J, Yildiz V, Pan X, Dowell JD. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases. J Vasc Interv Radiol 2016;27:1298-304. [PMID: 27499157 DOI: 10.1016/j.jvir.2016.05.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
208 Cheng AL, Amarapurkar D, Chao Y, Chen P, Geschwind J, Goh KL, Han K, Kudo M, Lee HC, Lee R, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan C, Tanwandee T, Teng G, Park J. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-83. [DOI: 10.1111/liv.12314] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
209 Somma F, D'Angelo R, Serra N, Gatta G, Grassi R, Fiore F. Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)? PLoS One 2015;10:e0129573. [PMID: 26110810 DOI: 10.1371/journal.pone.0129573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
210 Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol. 2011;197:W562-W570. [PMID: 21940527 DOI: 10.2214/ajr.10.4379] [Cited by in Crossref: 109] [Cited by in F6Publishing: 43] [Article Influence: 10.9] [Reference Citation Analysis]
211 Wang J, Cheng JJ, Huang KY, Zhuang ZG, Zhang XB, Chi JC, Hua XL, Xu JR. Quantitative assessment of angiographic perfusion reduction using color-coded digital subtraction angiography during transarterial chemoembolization. Abdom Radiol (NY) 2016;41:545-52. [PMID: 27039326 DOI: 10.1007/s00261-015-0622-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
212 Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012;33:33-40. [PMID: 21931992 DOI: 10.1007/s13277-011-0237-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
213 Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C. Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases. World J Gastroenterol 2013;19:3207-16. [PMID: 23745022 DOI: 10.3748/wjg.v19.i21.3207] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
214 Zhou B, Shan H, Zhu KS, Jiang ZB, Guan SH, Meng XC, Zeng XC. Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. J Vasc Interv Radiol. 2010;21:333-338. [PMID: 20116286 DOI: 10.1016/j.jvir.2009.11.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
215 Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer. 2011;11:202. [PMID: 21615953 DOI: 10.1186/1471-2407-11-202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
216 Liu FY, Wang MQ, Duan F, Fan QS, Song P, Wang Y. Hepatocellular carcinoma associated with Budd-Chiari syndrome: imaging features and transcatheter arterial chemoembolization. BMC Gastroenterol 2013;13:105. [PMID: 23800233 DOI: 10.1186/1471-230X-13-105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
217 Liang HY, Guo QY, Sun W, Mao XN, Wen F, Shan M, Zhao G, Wang XH, Lu ZM. Sequential Use of Transhepatic Arterial Chemoembolization and Bipolar Radiofrequency Ablation in the Clinical Therapy of Hepatocellular Carcinoma. Cancer Biother Radiopharm 2015;30:427-32. [PMID: 26683133 DOI: 10.1089/cbr.2015.1884] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
218 Kang JY, Choi MS, Kim SJ, Kil JS, Lee JH, Koh KC, Paik SW, Yoo BC. Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma. Korean J Hepatol. 2010;16:383-388. [PMID: 21415582 DOI: 10.3350/kjhep.2010.16.4.383] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
219 Ko HK, Ko GY, Yoon HK, Sung KB. Tumor response to transcatheter arterial chemoembolization in recurrent hepatocellular carcinoma after living donor liver transplantation. Korean J Radiol. 2007;8:320-327. [PMID: 17673843 DOI: 10.3348/kjr.2007.8.4.320] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
220 Lin CT, Hsu KF, Chen TW, Yu JC, Chan DC, Yu CY, Hsieh TY, Fan HL, Kuo SM, Chung KP, Hsieh CB. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg. 2010;34:2155-2161. [PMID: 20407768 DOI: 10.1007/s00268-010-0598-x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 5.5] [Reference Citation Analysis]
221 Guo JH, Zhu X, Li XT, Yang RJ. Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocellular carcinoma after transarterial chemoembolization. Chin J Cancer Res 2012;24:36-43. [PMID: 23359473 DOI: 10.1007/s11670-012-0036-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
222 Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. Lancet. 2009;373:614-616. [PMID: 19231618 DOI: 10.1016/s0140-6736(09)60381-0] [Cited by in Crossref: 205] [Cited by in F6Publishing: 101] [Article Influence: 17.1] [Reference Citation Analysis]
223 Pillai AA, Ramanathan M, Kulik L. Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years? Clin Liver Dis 2020;24:681-700. [PMID: 33012453 DOI: 10.1016/j.cld.2020.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
224 Wang X, Liu Y, Qin Q, Zheng T. Clusterin role in hepatocellular carcinoma patients treated with oxaliplatin. Biosci Rep 2020;40:BSR20200071. [PMID: 32039450 DOI: 10.1042/BSR20200071] [Reference Citation Analysis]
225 Huppert P. Current concepts in transarterial chemoembolization of hepatocellular carcinoma. Abdom Imaging. 2011;36:677-683. [PMID: 21674193 DOI: 10.1007/s00261-011-9755-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
226 Bouvier A, Ozenne V, Aubé C, Boursier J, Vullierme MP, Thouveny F, Farges O, Vilgrain V. Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 2011;21:1719-26. [PMID: 21479978 DOI: 10.1007/s00330-011-2118-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
227 Song MJ. Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865-873. [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
228 Wang P, Sheng L, Wang G, Wang H, Huang X, Yan X, Yang X, Pei R. Association of transarterial chemoembolization with survival in patients with unresectable hepatocellular carcinoma. Mol Clin Oncol 2014;2:203-6. [PMID: 24649333 DOI: 10.3892/mco.2014.239] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
229 Gaba RC. Chemoembolization Practice Patterns and Technical Methods Among Interventional Radiologists: Results of an Online Survey. American Journal of Roentgenology 2012;198:692-9. [DOI: 10.2214/ajr.11.7066] [Cited by in Crossref: 50] [Cited by in F6Publishing: 10] [Article Influence: 5.6] [Reference Citation Analysis]
230 Giannini EG, Risso D, Testa R, Trevisani F, Di Nolfo MA, Del Poggio P, Benvegnù L, Ludovico Rapaccini G, Farinati F, Zoli M. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4:1378-1384. [PMID: 17059899 DOI: 10.1016/j.cgh.2006.08.011] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 3.3] [Reference Citation Analysis]
231 Kim D, Lee JH, Moon H, Seo M, Han H, Yoo H, Seo H, Lee J, Hong S, Kim P, Lee HJ, Chung JW, Kim H. Development and evaluation of an ultrasound-triggered microbubble combined transarterial chemoembolization (TACE) formulation on rabbit VX2 liver cancer model. Theranostics 2021;11:79-92. [PMID: 33391462 DOI: 10.7150/thno.45348] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Majno P, Giostra E, Morel P, Hadengue A, Mentha G. Management of hepatocellular carcinoma in the waiting list before liver transplantation. Journal of Hepatology 2005;42:S134-43. [DOI: 10.1016/j.jhep.2004.12.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
233 Shim JH, Kim KM, Lee YJ, Ko GY, Yoon HK, Sung KB, Park KM, Lee SG, Lim YS, Lee HC. Complete necrosis after transarterial chemoembolization could predict prolonged survival in patients with recurrent intrahepatic hepatocellular carcinoma after curative resection. Ann Surg Oncol. 2010;17:869-877. [PMID: 20033326 DOI: 10.1245/s10434-009-0788-7] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
234 Kim PH, Gwon DI, Kim JW, Chu HH, Kim JH. The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization. Eur Radiol 2020;30:5650-62. [PMID: 32409860 DOI: 10.1007/s00330-020-06911-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Wang D, Gaba RC, Jin B, Riaz A, Lewandowski RJ, Ryu RK, Sato KT, Ragin AB, Kulik LM, Mulcahy MF, Salem R, Larson AC, Omary RA. Intraprocedural transcatheter intra-arterial perfusion MRI as a predictor of tumor response to chemoembolization for hepatocellular carcinoma. Acad Radiol 2011;18:828-36. [PMID: 21669349 DOI: 10.1016/j.acra.2011.02.016] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
236 Hung YH, Huang HL, Chen WC, Yen MC, Cho CY, Weng TY, Wang CY, Chen YL, Chen LT, Lai MD. Argininosuccinate lyase interacts with cyclin A2 in cytoplasm and modulates growth of liver tumor cells. Oncol Rep 2017;37:969-78. [PMID: 28035420 DOI: 10.3892/or.2016.5334] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
237 Greten TF, Manns MP, Korangy F. Immunotherapy of hepatocellular carcinoma. J Hepatol. 2006;45:868-878. [PMID: 17046096 DOI: 10.1016/j.jhep.2006.09.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 3.5] [Reference Citation Analysis]
238 Giannini EG, Bodini G, Corbo M, Savarino V, Risso D, Di Nolfo MA, Del Poggio P, Benvegn㙠L, Farinati F, Zoli M, Borzio F, Caturelli E, Chiaramonte M, Trevisani F; FOR THE ITALIAN LIVER CANCER (ITA.LI.CA.) GROUP. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2010;31:493-501. [DOI: 10.1111/j.1365-2036.2009.04198.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
239 Bordoni A, Cerny A, Bihl F, Alerci M, Mazzola P, Peverelli S, Marini G, Majno P, Mazzucchelli L, Spitale A. Survival of hepatocellular carcinoma patients is significantly improving: a population-based study from southern Switzerland. Cancer Epidemiology 2014;38:679-85. [DOI: 10.1016/j.canep.2014.09.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
240 Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:49-56. [PMID: 17296704 DOI: 10.1016/j.jvir.2006.10.005] [Cited by in Crossref: 95] [Cited by in F6Publishing: 95] [Article Influence: 6.8] [Reference Citation Analysis]
241 Liapi E, Georgiades CC, Hong K, Geschwind JF. Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol. 2007;10:2-11. [PMID: 17980314 DOI: 10.1053/j.tvir.2007.08.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
242 Kim JW, Seong J, Park MS, Kim KS, Park YN, Han KH, Keum KC, Lee IJ. Radiological-pathological correlation study of hepatocellular carcinoma undergoing local chemoradiotherapy and surgery: Radiotherapy for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2016;31:1619-27. [DOI: 10.1111/jgh.13334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
243 Ma W, Jia J, Wang S, Bai W, Yi J, Bai M, Quan Z, Yin Z, Fan D, Wang J, Han G. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics. 2014;4:736-744. [PMID: 24883123 DOI: 10.7150/thno.8725] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
244 Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330. [PMID: 18430871 DOI: 10.1148/radiol.2472061331] [Cited by in Crossref: 274] [Cited by in F6Publishing: 225] [Article Influence: 21.1] [Reference Citation Analysis]
245 Orgera G, Monfardini L, Della Vigna P, Zhang L, Bonomo G, Arnone P, Padrenostro M, Orsi F. High-intensity focused ultrasound (HIFU) in patients with solid malignancies: evaluation of feasibility, local tumour response and clinical results. Radiol Med. 2011;116:734-748. [PMID: 21293939 DOI: 10.1007/s11547-011-0634-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
246 Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G, Mamone G, Vizzini G, Luca A, Gridelli B. Predictive factors of tumor response to trans-catheter treatment in cirrhotic patients with hepatocellular carcinoma: a multivariate analysis of pre-treatment findings. World J Gastroenterol 2007;13:6022-6. [PMID: 18023093 DOI: 10.3748/wjg.v13.45.6022] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
247 Chua TC, Chu F, Butler SP, Quinn RJ, Glenn D, Liauw W, Morris DL. Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma. Cancer 2010;116:4069-77. [PMID: 20564150 DOI: 10.1002/cncr.25283] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
248 Guiu B, Minello A, Cottet V, Lepage C, Hillon P, Faivre J, Bouvier A. A 30-Year, Population-Based Study Shows Improved Management and Prognosis of Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology 2010;8:986-91. [DOI: 10.1016/j.cgh.2010.07.018] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
249 Riaz A, Miller FH, Kulik LM, Nikolaidis P, Yaghmai V, Lewandowski RJ, Mulcahy MF, Ryu RK, Sato KT, Gupta R. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303:1062-1069. [PMID: 20233824 DOI: 10.1001/jama.2010.262] [Cited by in Crossref: 140] [Cited by in F6Publishing: 122] [Article Influence: 12.7] [Reference Citation Analysis]
250 Kritzinger J, Klass D, Ho S, Lim H, Buczkowski A, Yoshida E, Liu D. Hepatic embolotherapy in interventional oncology: technology, techniques, and applications. Clin Radiol 2013;68:1-15. [PMID: 22917735 DOI: 10.1016/j.crad.2012.06.112] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
251 Choi TW, Kim HC, Lee JH, Yu SJ, Kang B, Hur S, Lee M, Jae HJ, Chung JW. The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas. Korean J Radiol. 2015;16:1283-1293. [PMID: 26576118 DOI: 10.3348/kjr.2015.16.6.1283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
252 Goh AS, Chung AY, Lo RH, Lau TN, Yu SW, Chng M, Satchithanantham S, Loong SL, Ng DC, Lim BC. A novel approach to brachytherapy in hepatocellular carcinoma using a phosphorous32 (32P) brachytherapy delivery device--a first-in-man study. Int J Radiat Oncol Biol Phys. 2007;67:786-792. [PMID: 17141975 DOI: 10.1016/j.ijrobp.2006.09.011] [Cited by in Crossref: 64] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
253 Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY, Chang UI, Yang JM, Lee HG, Yoon SK. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57:1244-1250. [PMID: 22824821 DOI: 10.1016/j.jhep.2012.07.017] [Cited by in Crossref: 135] [Cited by in F6Publishing: 131] [Article Influence: 15.0] [Reference Citation Analysis]
254 Altomonte J, Muñoz-Álvarez KA, Shinozaki K, Baumgartner C, Kaissis G, Braren R, Ebert O. Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats. J Vis Exp 2016. [PMID: 27167921 DOI: 10.3791/53757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
255 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
256 Siramolpiwat S, Punjachaipornpon T, Pornthisarn B, Vilaichone RK, Chonprasertsuk S, Tangaroonsanti A, Bhanthumkomol P, Phumyen A, Yasiri A, Kaewmanee M. N-Acetylcysteine Prevents Post-embolization Syndrome in Patients with Hepatocellular Carcinoma Following Transarterial Chemoembolization. Dig Dis Sci 2019;64:3337-45. [PMID: 31073737 DOI: 10.1007/s10620-019-05652-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
257 Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, Steven NM, Kerr DJ, Young LS, Adams DH. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology. 2009;49:124-132. [PMID: 18980227 DOI: 10.1002/hep.22626] [Cited by in Crossref: 169] [Cited by in F6Publishing: 149] [Article Influence: 14.1] [Reference Citation Analysis]
258 Kitisin K, Packiam V, Steel J, Humar A, Gamblin TC, Geller DA, Marsh JW, Tsung A. Presentation and outcomes of hepatocellular carcinoma patients at a western centre. HPB (Oxford) 2011;13:712-22. [PMID: 21929672 DOI: 10.1111/j.1477-2574.2011.00362.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
259 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 704] [Article Influence: 156.2] [Reference Citation Analysis]
260 Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, Gores G, Kerlan R, Merle P, O'Neil B, Poon R, Schwartz L, Tepper J, Yao F, Haller D, Mooney M, Venook A. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2010;28:3994-4005. [PMID: 20679622 DOI: 10.1200/jco.2010.28.7805] [Cited by in Crossref: 261] [Cited by in F6Publishing: 137] [Article Influence: 23.7] [Reference Citation Analysis]
261 Taouli B, Johnson RS, Hajdu CH, Oei MT, Merad M, Yee H, Rusinek H. Hepatocellular carcinoma: perfusion quantification with dynamic contrast-enhanced MRI. AJR Am J Roentgenol. 2013;201:795-800. [PMID: 24059368 DOI: 10.2214/ajr.12.9798] [Cited by in Crossref: 59] [Cited by in F6Publishing: 31] [Article Influence: 7.4] [Reference Citation Analysis]
262 Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A, Memeo V. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection? HPB (Oxford). 2007;9:429-434. [PMID: 18345289 DOI: 10.1080/13651820701713758] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 5.5] [Reference Citation Analysis]
263 Jia QA, Ren ZG, Bu Y, Wang ZM, Zhang QB, Liang L, Jiang XM, Zhang QB, Tang ZY. Herbal Compound "Songyou Yin" Renders Hepatocellular Carcinoma Sensitive to Oxaliplatin through Inhibition of Stemness. Evid Based Complement Alternat Med 2012;2012:908601. [PMID: 23326293 DOI: 10.1155/2012/908601] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
264 Mokdad AA, Singal AG, Yopp AC. Advances in Local and Systemic Therapies for Hepatocellular Cancer. Curr Oncol Rep 2016;18:9. [PMID: 26769114 DOI: 10.1007/s11912-015-0494-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
265 Hagan A, Phillips GJ, Macfarlane WM, Lloyd AW, Czuczman P, Lewis AL. Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies. Eur J Pharm Sci 2017;101:22-30. [PMID: 28132823 DOI: 10.1016/j.ejps.2017.01.033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
266 He CB, Lao XM, Lin XJ. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study. Chin J Cancer 2017;36:59. [PMID: 28728568 DOI: 10.1186/s40880-017-0227-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
267 Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract. Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. HPB (Oxford). 2010;12:313-320. [PMID: 20590905 DOI: 10.1111/j.1477-2574.2010.00183.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
268 Delicque J, Guiu B, Boulin M, Schwanz H, Piron L, Cassinotto C. Liver chemoembolization of hepatocellular carcinoma using TANDEM® microspheres. Future Oncol 2018;14:2761-72. [PMID: 29953255 DOI: 10.2217/fon-2018-0237] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
269 Shen A, Liu S, Yu W, Deng H, Li Q. p53 gene therapy-based transarterial chemoembolization for unresectable hepatocellular carcinoma: A prospective cohort study. J Gastroenterol Hepatol 2015;30:1651-6. [PMID: 25968838 DOI: 10.1111/jgh.13009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
270 Yi Y, Zhang Y, Wei Q, Zhao L, Han J, Song Y, Ding Y, Lu G, Liu J, Ding H, Dai F, Tang X. Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. Chin J Cancer Res 2014;26:112-8. [PMID: 24653633 DOI: 10.3978/j.issn.1000-9604.2014.02.09] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
271 Kim AY, Rhim H, Park M, Lee MW, Kim YS, Choi D, Lim HK. Venous thrombosis after radiofrequency ablation for hepatocellular carcinoma. AJR Am J Roentgenol. 2011;197:1474-1480. [PMID: 22109305 DOI: 10.2214/ajr.11.6495] [Cited by in Crossref: 19] [Cited by in F6Publishing: 3] [Article Influence: 2.1] [Reference Citation Analysis]
272 Yokoyama K, Anan A, Iwata K, Nishizawa S, Morihara D, Ueda S, Sakurai K, Iwashita H, Hirano G, Sakamoto M. Limitation of repeated radiofrequency ablation in hepatocellular carcinoma: proposal of a three (times) × 3 (years) index. J Gastroenterol Hepatol. 2012;27:1044-1050. [PMID: 22433056 DOI: 10.1111/j.1440-1746.2012.07134.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
273 Woo HY, Heo J. New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis. Clin Mol Hepatol 2015;21:115-21. [PMID: 26157747 DOI: 10.3350/cmh.2015.21.2.115] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
274 Hass P, Mohnike K. Extending the Frontiers Beyond Thermal Ablation by Radiofrequency Ablation: SBRT, Brachytherapy, SIRT (Radioembolization). Viszeralmedizin 2014;30:245-52. [PMID: 26288597 DOI: 10.1159/000366088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
275 Gu L, Liu H, Fan L, Lv Y, Cui Z, Luo Y, Liu Y, Li G, Li C, Ma J. Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2014;140:199-210. [PMID: 24077865 DOI: 10.1007/s00432-013-1528-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
276 Qian X, Zhang W, Shams A, Mohammed K, Befeler AS, Kang N, Lai J. Yes-associated protein-1 may serve as a diagnostic marker and therapeutic target for residual/recurrent hepatocellular carcinoma post-transarterial chemoembolization. Liver Res 2020;4:212-7. [PMID: 33520338 DOI: 10.1016/j.livres.2020.11.002] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
277 Abdo AA, Hassanain M, AlJumah A, Al Olayan A, Sanai FM, Alsuhaibani HA, Abdulkareem H, Abdallah K, AlMuaikeel M, Al Saghier M, Babatin M, Kabbani M, Bazarbashi S, Metrakos P, Bruix J; Saudi Association for the Study of Liver Diseases and Transplantation., Saudi Oncology Society. Saudi guidelines for the diagnosis and management of hepatocellular carcinoma: technical review and practice guidelines. Ann Saudi Med 2012;32:174-99. [PMID: 22366832 DOI: 10.5144/0256-4947.2012.174] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
278 Merle P, Mornex F. [Transarterial chemoembolization and conformal radiotherapy for hepatocellular carcinoma]. Cancer Radiother 2011;15:69-71. [PMID: 21237690 DOI: 10.1016/j.canrad.2010.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
279 Shiozawa K, Watanabe M, Ikehara T, Kogame M, Kikuchi Y, Igarashi Y, Sumino Y. Therapeutic evaluation of sorafenib for hepatocellular carcinoma using contrast-enhanced ultrasonography: Preliminary result. Oncol Lett. 2016;12:579-584. [PMID: 27347183 DOI: 10.3892/ol.2016.4669] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
280 Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol. 2007;13:3164-3170. [PMID: 17589893 DOI: 10.3748/wjg.v13.i23.3164] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
281 Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011;258:627-634. [PMID: 21273524 DOI: 10.1148/radiol.10101058] [Cited by in Crossref: 165] [Cited by in F6Publishing: 149] [Article Influence: 16.5] [Reference Citation Analysis]
282 Youn BJ, Chung JW, Son KR, Kim H, Jae HJ, Lee JM, Song IC, Kim I, Park JH. Diffusion-Weighted MR. Academic Radiology 2008;15:593-600. [DOI: 10.1016/j.acra.2007.10.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
283 Hoofnagle JH. Hepatocellular carcinoma: summary and recommendations. Gastroenterology 2004;127:S319-23. [PMID: 15508100 DOI: 10.1053/j.gastro.2004.09.047] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
284 Kiefer MV, Albert M, Mcnally M, Robertson M, Sun W, Fraker D, Olthoff K, Christians K, Pappas S, Rilling W, Soulen MC. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: A 2-center study. Cancer 2011;117:1498-505. [DOI: 10.1002/cncr.25625] [Cited by in Crossref: 88] [Cited by in F6Publishing: 70] [Article Influence: 8.0] [Reference Citation Analysis]
285 Jihye C, Jinsil S. Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma. Liver Cancer 2012;1:216-25. [PMID: 24159586 DOI: 10.1159/000343836] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
286 Boige V, Taïeb J, Hebbar M, Malka D, Debaere T, Hannoun L, Magherini E, Mignard D, Poynard T, Ducreux M. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer 2006;42:456-9. [PMID: 16427779 DOI: 10.1016/j.ejca.2005.09.034] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
287 Kim HJ, Shin JH, Kim T, Kim EY, Park YS, Park C, Song H. Efficacy of Transarterial Embolization with Arsenic Trioxide Oil Emulsion in a Rabbit VX2 Liver Tumor Model. Journal of Vascular and Interventional Radiology 2009;20:1365-70. [DOI: 10.1016/j.jvir.2009.07.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
288 El-serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology 2008;134:1752-63. [DOI: 10.1053/j.gastro.2008.02.090] [Cited by in Crossref: 690] [Cited by in F6Publishing: 610] [Article Influence: 53.1] [Reference Citation Analysis]
289 Tovoli F, Negrini G, Bolondi L. Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma. Hepat Oncol 2016;3:119-36. [PMID: 30191033 DOI: 10.2217/hep-2015-0006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
290 Yamamoto K, Yamanaka K, Hatano E, Sumi E, Ishii T, Taura K, Iguchi K, Teramukai S, Yokode M, Uemoto S, Fukushima M. An eClinical trial system for cancer that integrates with clinical pathways and electronic medical records. Clin Trials 2012;9:408-17. [PMID: 22605791 DOI: 10.1177/1740774512445912] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
291 Rammohan A, Sathyanesan J, Ramaswami S, Lakshmanan A, Senthil-Kumar P, Srinivasan UP, Ramasamy R, Ravichandran P. Embolization of liver tumors: Past, present and future. World J Radiol. 2012;4:405-412. [PMID: 23024842 DOI: 10.4329/wjr.v4.i9.405] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 35] [Article Influence: 4.9] [Reference Citation Analysis]
292 Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Lok AS. Reply:. Hepatology 2005;42:739-40. [DOI: 10.1002/hep.20863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
293 Gross A, Albrecht T. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. Cardiovasc Intervent Radiol 2020;43:402-10. [PMID: 31705244 DOI: 10.1007/s00270-019-02364-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
294 Kim IS, Lim YS, Lee HC, Suh DJ, Lee YJ, Lee SG. Pre-operative transarterial chemoembolization for resectable hepatocellular carcinoma adversely affects post-operative patient outcome. Aliment Pharmacol Ther 2008;27:338-45. [PMID: 18047564 DOI: 10.1111/j.1365-2036.2007.03580.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
295 Nicolini A, Fasani P, Manini MA, Martinetti L, Forzenigo LV, Iavarone M, Crespi S, Rossi G, Biondetti P, Colombo M, Sangiovanni A. Transarterial embolization with microspheres in the treatment of monofocal HCC. Dig Liver Dis 2009;41:143-9. [PMID: 18436490 DOI: 10.1016/j.dld.2008.03.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
296 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 10.5] [Reference Citation Analysis]
297 Liu D, Liu F, Xie X, Su L, Liu M, Kuang M, Huang G, Wang Y, Zhou H, Wang K, Lin M, Tian J. Accurate prediction of responses to transarterial chemoembolization for patients with hepatocellular carcinoma by using artificial intelligence in contrast-enhanced ultrasound. Eur Radiol. 2020;30:2365-2376. [PMID: 31900703 DOI: 10.1007/s00330-019-06553-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 27.0] [Reference Citation Analysis]
298 Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Reference Citation Analysis]
299 Forner A, Ayuso C, Isabel Real M, Sastre J, Robles R, Sangro B, Varela M, de la Mata M, Buti M, Martí-Bonmatí L, Bru C, Tabernero J, Llovet JM, Bruix J. [Diagnosis and treatment of hepatocellular carcinoma]. Med Clin (Barc) 2009;132:272-87. [PMID: 19248879 DOI: 10.1016/j.medcli.2008.11.024] [Cited by in Crossref: 56] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
300 Zou LQ, Zhang BL, Chang Q, Zhu FP, Li YY, Wei YQ, Guan YS. 3D conformal radiotherapy combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2014;20:17227-17234. [PMID: 25493039 DOI: 10.3748/wjg.v20.i45.17227] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
301 Bryant MK, Dorn DP, Zarzour J, Smith JK, Redden DT, Saddekni S, Abdel Aal AK, Gray SH, Eckhoff DE, Dubay DA. Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. HPB (Oxford). 2014;16:327-335. [PMID: 23980917 DOI: 10.1111/hpb.12149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
302 Miura JT, Gamblin TC. Transarterial chemoembolization for primary liver malignancies and colorectal liver metastasis. Surg Oncol Clin N Am 2015;24:149-66. [PMID: 25444473 DOI: 10.1016/j.soc.2014.09.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
303 Gwon D, Ko G, Yoon H, Sung K, Kim JH, Lee SS, Lee JM, Ohm J, Shin JH, Song H. Hepatocellular Carcinoma Associated with Membranous Obstruction of the Inferior Vena Cava: Incidence, Characteristics, and Risk Factors and Clinical Efficacy of TACE. Radiology 2010;254:617-26. [DOI: 10.1148/radiol.09090738] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
304 Fuchs K, Bize PE, Denys A, Borchard G, Jordan O. Sunitinib-eluting beads for chemoembolization: Methods for in vitro evaluation of drug release. International Journal of Pharmaceutics 2015;482:68-74. [DOI: 10.1016/j.ijpharm.2014.11.041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
305 Kim HC, Suk KT, Kim DJ, Yoon JH, Kim YS, Baik GH, Kim JB, Kim CH, Sung H, Choi JY, Han KH, Park SH. Transarterial chemoembolization in Barcelona Clinic Liver Cancer Stage 0/A hepatocellular carcinoma. World J Gastroenterol 2014;20:745-54. [PMID: 24574748 DOI: 10.3748/wjg.v20.i3.745] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
306 Liapi E, Geschwind JF. Intra-arterial therapies for hepatocellular carcinoma: where do we stand? Ann Surg Oncol. 2010;17:1234-1246. [PMID: 20405328 DOI: 10.1245/s10434-010-0977-4] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
307 Welker MW, Trojan J. Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. Cancer Manag Res 2013;5:337-47. [PMID: 24204170 DOI: 10.2147/CMAR.S35029] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
308 Ni JY, Kong J, Sun HL, Chen YT, Luo JH, Wang WD, Chen D, Jiang XY, Xu LF. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas. Acad Radiol 2018;25:423-9. [PMID: 29198946 DOI: 10.1016/j.acra.2017.10.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
309 Lencioni R. Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. Crit Rev Oncol Hematol. 2012;83:216-224. [PMID: 22142656 DOI: 10.1016/j.critrevonc.2011.10.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
310 Chen CA, Lo CK, Lin BL, Sibley E, Tang SC. Application of doxorubicin-induced rAAV2-p53 gene delivery in combined chemotherapy and gene therapy for hepatocellular carcinoma. Cancer Biol Ther 2008;7:303-9. [PMID: 18059187 DOI: 10.4161/cbt.7.2.5333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
311 He MK, Zou RH, Wei W, Shen JX, Zhao M, Zhang YF, Lin XJ, Zhang YJ, Guo RP, Shi M. Comparison of Stable and Unstable Ethiodized Oil Emulsions for Transarterial Chemoembolization of Hepatocellular Carcinoma: Results of a Single-Center Double-Blind Prospective Randomized Controlled Trial. J Vasc Interv Radiol 2018;29:1068-1077.e2. [PMID: 30042075 DOI: 10.1016/j.jvir.2018.03.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
312 Trinchet JC, Ganne-Carrié N, Nahon P, N'kontchou G, Beaugrand M. Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol 2007;13:2455-60. [PMID: 17552029 DOI: 10.3748/wjg.v13.i17.2455] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
313 Min JH, Lee MW, Rhim H, Choi D, Kim YS, Kim YJ, Cha DI, Lim HK. Radiofrequency ablation for viable hepatocellular carcinoma around retained iodized oil after transcatheter arterial chemoembolization: usefulness of biplane fluoroscopy plus ultrasound guidance. Korean J Radiol. 2012;13:784-794. [PMID: 23118578 DOI: 10.3348/kjr.2012.13.6.784] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
314 Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau G, Luca A, del Arbol LR, Leberre M, Niu W, Nicholson K, Meinhardt G, Bruix J. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. Journal of Hepatology 2016;64:1090-8. [DOI: 10.1016/j.jhep.2016.01.012] [Cited by in Crossref: 296] [Cited by in F6Publishing: 271] [Article Influence: 59.2] [Reference Citation Analysis]
315 Shiozawa K, Watanabe M, Ikehara T, Yamamoto S, Matsui T, Saigusa Y, Igarashi Y, Maetani I. Efficacy of intra-arterial contrast-enhanced ultrasonography during transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. World J Hepatol 2018;10:95-104. [PMID: 29399283 DOI: 10.4254/wjh.v10.i1.95] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
316 Roth CG, Mitchell DG. Hepatocellular carcinoma and other hepatic malignancies: MR imaging. Radiol Clin North Am. 2014;52:683-707. [PMID: 24889167 DOI: 10.1016/j.rcl.2014.02.015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
317 Ni JY, Xu LF, Wang WD, Huang QS, Sun HL, Chen YT. Transarterial embolization combined with RNA interference targeting hypoxia-inducible factor-1α for hepatocellular carcinoma: a preliminary study of rat model. J Cancer Res Clin Oncol 2017;143:199-207. [PMID: 27638772 DOI: 10.1007/s00432-016-2237-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
318 Hectors SJ, Wagner M, Besa C, Bane O, Dyvorne HA, Fiel MI, Zhu H, Donovan M, Taouli B. Intravoxel incoherent motion diffusion-weighted imaging of hepatocellular carcinoma: Is there a correlation with flow and perfusion metrics obtained with dynamic contrast-enhanced MRI? J Magn Reson Imaging 2016;44:856-64. [PMID: 26919327 DOI: 10.1002/jmri.25194] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 6.4] [Reference Citation Analysis]
319 Han SH, Reddy KR, Keeffe EB, Soldevila-Pico C, Gish R, Chung RT, Degertekin B, Lok A; NIH HBV OLT Study Group. Clinical outcomes of liver transplantation for HBV-related hepatocellular carcinoma: data from the NIH HBV OLT study. Clin Transplant 2011;25:E152-62. [PMID: 21077950 DOI: 10.1111/j.1399-0012.2010.01349.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
320 Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB, Mulcahy MF. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497-507.e2. [PMID: 21044630 DOI: 10.1053/j.gastro.2010.10.049] [Cited by in Crossref: 390] [Cited by in F6Publishing: 339] [Article Influence: 35.5] [Reference Citation Analysis]
321 Wang K, Liu G, Li J, Yan Z, Xia Y, Wan X, Ji Y, Lau WY, Wu M, Shen F. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study. Eur J Surg Oncol 2015;41:236-42. [PMID: 25434327 DOI: 10.1016/j.ejso.2014.11.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
322 Zarrinpar A, Kaldas F, Busuttil RW. Liver transplantation for hepatocellular carcinoma: an update. Hepatobiliary & Pancreatic Diseases International 2011;10:234-42. [DOI: 10.1016/s1499-3872(11)60039-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]